Compare iShares MSCI Canada (TSX) (EWC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Sanofi SA — how do they compare? iShares MSCI Canada (TSX) trades at $61.69, while Sanofi SA trades at $43.54 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while iShares MSCI Canada (TSX) pays none, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| EWC | SNY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $61.51 | $52.34 |
52-Week Low | $47.00 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $61.81, up 0.5% on the day, with a bullish technical signal driven by moving averages but caution from overbought RSI levels. The ETF shows strong performance in 2026 with double-digit returns, though it trails the S&P 500. Recent news highlights trade tensions with the U.S., including potential 50% tariffs on Canadian goods, but key exclusions may limit material impact.
Outlook remains cautiously optimistic due to Canada's economic resilience and active ETF market growth. Risks include trade war escalation and commodity price volatility, but analyst sentiment supports bullish positioning for diversified exposure to Canadian equities.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
